Metastatic Cancer Treatment Market, By Product (Branded Medicines and Generic Medicines), By Therapeutic Indication (Breast Cancer, Melanoma, Lung Cancer, Prostate Cancer, Colorectal Cancer, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034

Report Code: PMI384820 | Publish Date: March 2024 | No. of Pages: 178

Global Metastatic Cancer Treatment Market Overview

Introduction:

Metastatic Cancer Treatment Market was valued at US$ 57.5 Billion in 2024 and is projected to grow at a CAGR of 7.2% to reach US$ 108.5 Billion by 2034.

Metastatic Cancer Treatment Market  is a cancer type which spreads in different body part from where it started. Metastases develop most commonly when cancer cells break away from the main tumour and enter the bloodstream or lymphatic system. These systems carry fluids around the body. This means that cancer cells can spread locally by moving into nearby normal tissue also spread regionally, to nearby lymph nodes, tissues, or organs. It can spread to distant parts of the body. This condition is called metastatic cancer and the process by which cancer cells spread to other parts of the body is called metastasis. Treatment of metastatic cancer is mainly aimed at slowing the growth or spread of cancer and boot out the symptoms caused by it. The type of treatments strategies commonly used to treat metastatic cancer includes chemotherapy and other drug therapies, hormone therapies, radiation therapy, surgery and ablation therapy, surrounded by others.

Drivers and Restraints:

The growing concerns of death rates due to cancer globally and high unfilled to medical needs of patients who have metastatic cancer are expected to increase the adoption rate of cancer therapy, as a result accelerating the growth of the target market. For instance, according to WHO cancer is the second primary cause of death globally, and is estimated at 9.6 million deaths in 2018 globally. Worldwide 1 in 6 deaths is due to cancer. Additionally, the increase in tobacco use is leading to cause cancer such factor boost the target market growth. For instance, according to WHO tobacco use is the most important risk factor for cancer and is responsible for around 22% of cancer deaths. Moreover, progresses in immuno-oncology and precision medicine are expected to fuel the target market growth. Also, the upsurge in research and development activities and the rising adoption of biologics and biosimilar for the treatment of cancers is supporting the growth of the target market. Furthermore, patients all over the world are looking forward to progressive cancer therapy drugs to arrest their condition, which in turn is increasing the adoption rate of metastatic cancer treatment. However, unavailability of such treatment restrains the target market growth.

Segmentation:

The metastatic cancer treatment market is segmented based on the product, therapeutic Indication, and region.

Based on products, the metastatic cancer treatment market classified into branded medicines and generic medicines. The generic medicine is accounted for higher growth rate because of the availability of cancer treatment drugs at an affordable price. Based on therapeutic Indication, the metastatic cancer treatment market classified into six major cancer type's breast cancer, melanoma, lung cancer, prostate cancer, colorectal cancer, and others. Breast cancer is the leading contributor to metastatic cancer treatment market. For instance, according to Cancer.Net around 6% of women have metastatic cancer when they are first diagnosed with breast cancer.

Based on the region, the metastatic cancer treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the target market, owing to Cancer has a major impact on society in the United States and the growing prevalence of breast cancer. For instance, according to ACS journals, around 3.8 million women living in the United States are suffering from invasive breast cancer, and around 268,600 women will be newly diagnosed in 2019. Also, around 150,000 breast cancer survivors are living with metastatic disease. Asia-Pacific is expected to show the highest CAGR owing to increasing R&D in the region and growing awareness about cancer. 

Key Players:   

The key players operating the metastatic cancer treatment market involves AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb Company, Celgene Corporation, Clovis Oncology, and Eli Lilly and Company. The key player in the market is focusing on research and development. For instance, in January 2019 AbbVie provided an update on Phase 3 study of Ibrutinib (IMBRUVICA®) in Metastatic Pancreatic Cancer.

Detailed Segmentation:

Metastatic Cancer Treatment Market, By Product:

  • Branded Medicines
  • Generic Medicines

 Metastatic Cancer Treatment Market, By Therapeutic Indication:

  • Breast Cancer
  • Melanoma
  • Lung Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Others

Metastatic Cancer Treatment Market, By Region:

  • North America
    • Middle East & Africa
      • Middle East & Africa Metastatic Cancer Treatment Market, By Product
      • Middle East & Africa Metastatic Cancer Treatment Market, By Therapeutic Indication
      • Middle East & Africa Metastatic Cancer Treatment Market, By Country
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa
    • Latin America
      • Latin America Metastatic Cancer Treatment Market, By Product
      • Latin America Metastatic Cancer Treatment Market, By Therapeutic Indication
      • Latin America Metastatic Cancer Treatment Market, By Country
        • Brazil
        • Mexico
        • Rest of Latin America
    • Asia Pacific
      • Asia Pacific Metastatic Cancer Treatment Market, By Product
      • Asia Pacific Metastatic Cancer Treatment Market, By Therapeutic Indication
      • Asia Pacific Metastatic Cancer Treatment Market, By Country
        • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Europe
      • Europe Metastatic Cancer Treatment Market, By Product
      • Europe Metastatic Cancer Treatment Market, By Therapeutic Indication
      • Europe Metastatic Cancer Treatment Market, By Country
        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • North America Metastatic Cancer Treatment Market, By Product
    • North America Metastatic Cancer Treatment Market, By Therapeutic Indication
    • North America Metastatic Cancer Treatment Market, By Country
      • U.S.
      • Canada

Company Profile:

  • AbbVie Inc.
    • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim
  • Bristol Myers Squibb Company
  • Celgene Corporation
  • Clovis Oncology
  • Eli Lilly and Company

 “*” marked represents similar segmentation in other categories in the respective section

Global Metastatic Cancer Treatment Market Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Industry Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for Metastatic Cancer Treatment Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Products
      • Market Snippet, By Therapeutic indication
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Global Metastatic Cancer Treatment Market, By Products, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Branded medicines
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Generic medicines
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  6. Global Metastatic Cancer Treatment Market, By Therapeutic indication, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Breast Cancer
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Melanoma
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Lung Cancer
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Prostate Cancer
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Colorectal Cancer
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  7. Global Metastatic Cancer Treatment Market, By Region, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Mn), By Products, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Therapeutic indication, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Mn), By Products, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Therapeutic indication, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Mn), By Products, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Therapeutic indication, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Mn), By Products, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Therapeutic indication, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Mn), By Products, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Therapeutic indication, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  9. Company Profiles
  • AbbVie Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim
  • Bristol Myers Squibb Company
  • Celgene Corporation
  • Clovis Oncology
  • Eli Lilly and Company
  1. The Last Word
    • Future Impact
    • About Us
    • Contact

FAQs

The metastatic cancer treatment market is segmented based on the product, therapeutic Indication, and region.

the development of targeted therapies, the focus on immunotherapy and combination treatments, and advancements in precision medicine approaches, presenting significant opportunities in the global Metastatic Cancer Treatment Market.

increasing incidence of metastatic cancers, advancements in understanding cancer biology, the rise of personalized medicine, and the continuous development of novel cancer therapeutics.

North America and Europe are expected to dominate the Metastatic Cancer Treatment Market, driven by a high prevalence of metastatic cancers, advanced healthcare infrastructure, and significant research and development activities in these regions.

The key players operating the global metastatic cancer treatment market involves AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb Company, Celgene Corporation, Clovis Oncology, and Eli Lilly and Company.